替格瑞洛对急性非ST段抬高型心肌梗死(NSTEMI)患者PCI术后的临床疗效影响

Effect of tegrarol on the clinical effect of PCI in patientswith acute non ST elevation myocardial infarction(NSTEMI)

目的探究替格瑞洛对急性非ST段抬高型心肌梗死(non ST elevation myocardial infarction,NSTEMI)患者PCI术后的临床疗效。方法选取2017年3月至2019年3月本院行PCI手术治疗的70例NSTEMI患者,经计算机筛选后分为对照组和观察组,各35例。对照组采用氯吡格雷治疗,观察组采用替格瑞洛治疗,比较两组炎性因子、不良心脏事件及药物不良反应。结果术后1个月,观察组炎症因子浓度显著低于对照组(P<0.05);观察组不良心脏事件发生率为11.43%,低于对照组的31.43%(P<0.05);观察组药物不良反应发生率为8.57%,低于对照组的20.00%。结论NSTEMI患者行PCI治疗后,替格瑞洛应用价值较高,可缓解炎症,减少不良心脏事件发生,且不良反应较少,值得临床推广。

Objective To analyze the clinical effect of tegrilol on patients with acute non ST elevation myocardial infarction(NSTEMI)after PCI.Methods 70 patients with NSTEMI undergoing PCI from March 2017 to March 2019 in our hospital were divided into control group and observation group after screening by computer,with 35 cases in each group.The control group was treated with clopidogrel,and the observation group was treated with tegrarol,comparing inflammatory factors,adverse cardiac events and drug side effects.Results One month after operation,the concentration of inflammatory factors in the observation group was significantly lower than that in the control group(P<0.05).The incidence of adverse cardiac events in the observation group was 11.43%,which was lower than 31.43%in the control group(P<0.05).The incidence of adverse drug reactions in the observation group was 8.57%,which was lower than 20.00%in the control group.Conclusion Before and after PCI in NSTEMI,tegrarol has high value of application,can alleviate inflammation,reduce adverse cardiac events,and has fewer side effects,so it is recommended to promote.